Aurinia Pharmaceuticals Aktie
14,22
EUR
-0,10
EUR
-0,66
%
16,49
USD
+0,34
USD
+2,11
%
Aurinia Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Aurinia Pharmaceuticals Aktie Analyse
| 16.03.18 | Aurinia Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 08.02.18 | Aurinia Pharmaceuticals Outperform | RBC Capital Markets | |
| 30.10.17 | Aurinia Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 18.05.17 | Aurinia Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 11.04.17 | Aurinia Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 22.03.17 | Aurinia Pharmaceuticals Outperform | FBR & Co. | |
| 30.12.16 | Aurinia Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 30.06.16 | Aurinia Pharmaceuticals Buy | H.C. Wainwright & Co. | |
|
Werbung
|
|||
| 08.05.15 | Aurinia Pharmaceuticals Buy | MLV Capital | |
Werbung
Werbung